ATTICUS

Apixaban for treatment of embolic stroke of undetermined source

01/10/2015 to 28/02/2021

Study Design: ATTICUS is a multicentre (national, Germany), randomized, blinded, parallel group, active controlled, phase III clinical trial with adaptive study design.
Patient population: Max. total number of 600 patients with Embolic Stroke of Undetermined Source (ESUS) and at least one risk factor for cardiac embolism.
Aim of Study: Show superior efficacy of apixaban over aspirin (standard of care) in reduction of new ischemic lesions detected by MRI in patients with ESUS, and to show safety (similar risk of major and clinically non-major bleedings defined by ISTH criteria) compared to standard of care.